IDEMIA
26.6.2020 10:32:12 CEST | Business Wire | Press release
IDEMIA teamed up with Treezor over three years ago to develop a broad range of groundbreaking products like metal cards and new look / new-feel cards – colored layers, bushed metal finish, transparent - targeting key French neobanks and fintechs.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200626005102/en/
This collaboration between IDEMIA, the global leader in Augmented Identity and Treezor the French banking-as-a-service market leader, has today culminated in the launch of the first ever eco-friendly card by a fintech in France. This move ties in with both companies’ green initiatives while meeting consumer demand for sustainable solutions.
Backed by longstanding design, development and production know-how, IDEMIA was able to offer Treezor a low-natural-resource-consuming card without compromising at all on security or end-user convenience. As part of its environmental strategy, IDEMIA reaffirms its commitment to move away from today’s linear take-make-waste model and fundamentally rethink the way we design, use and reuse plastics.
Onlyone, first eco-friendly neobank1
Onlyone2 , a startup that markets itself as the first ever genuinely environmentally friendly fintech, will be the first recipient of this new 85+% recycled PVC card that is due to be launched with its existing customers in September 2020.
“We strive to adopt green practices throughout our operations by going paperless and developing digital and eco-friendly bank card solutions. Bank cards are manufactured from industrial waste-based recycled PVC in line with circular economy principles, which seek to cut waste of natural resources and minimize industrial waste. IDEMIA also obtained “Environmental Claim Validation Summary” certification from its recycled PVC supplier “UL Environment Inc.” said Amanda Gourbault, Executive Vice-President for Financial institutions activities at IDEMIA.
"We are grateful Treezor and IDEMIA give us this amazing opportunity to be the first Fintech in France to offer an eco-responsible card. With this new card, we are laying the first brick in supporting our customers towards a low-carbon lifestyle" said Kamel Nait Outaleb, Co-founder and CEO of Onlyone .
“We are proud that Onlyone will issue this very first card that embraces our and Onlyone’s values and meets today’s consumer expectations. We are thrilled to have a chance to contribute to #Tech4Good who share what we are trying to achieve. A big thank you to IDEMIA for bringing its technological expertise” said Eric Lassus, Treezor cofounder and CEO.
About IDEMIA
IDEMIA, the global leader in Augmented Identity, provides a trusted environment enabling citizens and consumers alike to perform their daily critical activities (such as pay, connect and travel), in the physical as well as digital space.
Securing our identity has become mission critical in the world we live in today. By standing for Augmented Identity, an identity that ensures privacy and trust and guarantees secure, authenticated and verifiable transactions, we reinvent the way we think, produce, use and protect one of our greatest assets – our identity – whether for individuals or for objects, whenever and wherever security matters. We provide Augmented Identity for international clients from Financial, Telecom, Identity, Public Security and IoT sectors.
With close to 15,000 employees around the world, IDEMIA serves clients in 180 countries.
For more information, visit www.idemia.com / Follow @IdemiaGroup on Twitter
About Onlyone:
Created at the end of 2018, Onlyone is an independent, 100% digital, ethical and positive impact Fintech. Founded by Kamel Naït-Outaleb, Amine Melouk and Matthias Rouberol, three experienced entrepreneurs in banking and digital, its mission is to create a different, more virtuous payment account model, in order to reposition the banking world at the heart of society and the realities of our time.
To meet social and environmental challenges, Onlyone is reinventing account management services, adapting them to help create a transparent and sustainable banking world. In addition to monitoring day-to-day account operations, Fintech enables its users to understand, monitor and reduce the environmental impact of their consumption thanks to an exclusive environmental impact score and change management tools. It also enables them to contribute to financing projects with a high social and environmental impact, such as carbon offsetting projects or the fight against malnutrition, in a simple way and at no extra cost. To find out more go to Onlyonecard.eu.
About Treezor
Éric Lassus and Xavier Labouret founded Treezor in 2016 and in 2019 sold it to French bank Société Générale. Today Treezor is a French white-label payment services fintech. The firm can market its services in Europe based on its electronic money operating license and its Mastercard principal member status. The firm manages the entire payment process via its platform encompassing purchase, card issue, Xpay, wire transfers, P2P, KYC and more. The firm dedicates a large proportion of its funds to developing new technologies and has 80-plus staff in Paris and Rennes. To learn more about Treezor, go to www.treezor.com , follow us on Twitter @TreezorBanking and on our LinkedIn page.
----------------------------
1
As defined by the French Prudential Supervision and Resolution Authority in its 2019 report titled “Neobanks seeking profits”, ‘neobank’ means Banking-as-a-Service platforms like Treezor.
2
Treezor payment services agent
View source version on businesswire.com: https://www.businesswire.com/news/home/20200626005102/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Doubtless Pet Care Launches to Provide Peace of Mind to Pet Parents and Help Their Pets Live Happier, Healthier Lives29.6.2026 10:15:00 CEST | Press release
Doubtless combines industry-leading pet insurance with innovative care solutions, protecting more than 6 million pets across 10 global markets Doubtless launches today with the goal of helping more pet parents across the world access quality care for the pets they love. The company brings together a leading global portfolio of pet insurance brands with a growing range of connected solutions designed to support pet parents at every stage of their pet’s life. With over 4,000 employees, Doubtless insures 6 million pets across 10 markets in North America, Europe and the United Kingdom. “Uncertainty about the financial commitments associated with having a pet should never keep families from experiencing the joy of a life with pets,” said Dirk Beeckman, CEO of Doubtless. “By harnessing the power of our international footprint, we are building on our leadership in pet insurance to create a global suite of solutions for pet parents, veterinarians and industry partners that makes pet care easie
Samsung Bioepis Announces Positive Preliminary Phase 1 and Phase 3 Data for SB27, a Proposed Biosimilar to Keytruda (Pembrolizumab)29.6.2026 09:19:00 CEST | Press release
Phase 1 study demonstrated pharmacokinetic (PK) equivalence between SB27 and Keytruda; Phase 3 study demonstrated equivalent objective response rate (ORR) at Week 24Phase 1 and Phase 3 studies expected to be completed within 2026 Samsung Bioepis Co., Ltd. announced today that the Phase 1 and Phase 3 studies on SB27, a proposed biosimilar to Keytruda1 (pembrolizumab), have met their primary endpoints. “We are excited to announce preliminary results from the Phase 1 and Phase 3 studies for SB27, our pembrolizumab biosimilar candidate. These topline positive results reinforce our scientific expertise and leadership in biosimilar development,” said Donghoon Shin, Executive Vice President and Head of Clinical Sciences Division at Samsung Bioepis. “We are on track to complete both Phase 1 and Phase 3 studies within this year. Leveraging our robust quality management system, we remain committed to advancing our biosimilar portfolio to broaden access to life-saving biologic medicines for patie
IQM Named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment29.6.2026 09:00:00 CEST | Press release
IQM today announced it has been named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260629748732/en/ IQM named a major player in the IDC MarketScape IQM believes this recognition comes as institutions worldwide move quantum computing out of shared cloud access and into infrastructure they own and operate themselves. IQM calls this Production Quantum: full-stack, open-architecture superconducting systems deployed on premises, inside customers' own data centers and HPC environments, where organizations own the hardware, build internal expertise, and run quantum processors alongside their existing classical infrastructure. According to the IDC MarketScape, "For institutions building long-term quantum programs, this means the workflows and intellectual property developed on IQM hardware remain portable." The report further advises: "Consi
Zambon Announces Positive CHMP Opinion for Hopledo® (IPX203) for Adults with Parkinson’s Disease and Moderate to Severe Motor Fluctuations29.6.2026 09:00:00 CEST | Press release
Positive CHMP opinion is based on data from the Phase 3 RISE-PD trial, which demonstrated significantly more “Good ON” time with fewer daily doses compared with immediate-release levodopa/carbidopa More than one million people are living with Parkinson’s disease in the European Union, and over 80% experience motor fluctuations during the course of their disease, highlighting the need for additional treatment options Hopledo® contains a unique formulation combining immediate-release granules and extended-release pellets, providing both a rapid onset of action and a longer duration of effect, sustaining the levodopa therapeutic effect for a longer period of time If approved, Zambon expects to make Hopledo® progressively available to patients with Parkinson’s disease across Europe starting October 2026 Zambon today announced that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the granting of a marketing authorization by the European M
Enhertu® Approved in the EU as First Tumor Agnostic HER2 Directed Therapy and Antibody Drug Conjugate for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors29.6.2026 08:30:00 CEST | Press release
Approval based on three phase 2 trials of Daiichi Sankyo and AstraZeneca’s Enhertu that demonstrated clinically meaningful responses across a broad range of tumors Enhertu now approved for six indications in the EU Enhertu® (trastuzumab deruxtecan) has been approved in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinion of the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from subgroups of patients with HER2 positive (IHC 3+) tumors across thr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
